Swedish researchers find that daily cortisone eye drops reduce the chance that babies with ROP will require further invasive interventions ...
FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...
The first cell rejuvenation therapy is set to enter clinics, testing if aging cells can be reset to a younger, healthier ...
(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the first patient dosed in ...
Hi. Good morning, everyone. I'm Ellie Merle, one of the biotech analysts here at Barclays. Thank you for joining us here in Sunny Miami. Very happy to have 4D Molecular Therapeutics here with us today ...
Current treatments for corneal neovascularization rely on invasive intravitreal injections, which limit patient compliance and carry significant risks. To address this, researchers developed a ...
Ophthalmology is the highest volume outpatient specialty within the NHS and the medicines used for medical retinal vascular conditions account for some of the highest cost and volume treatments used ...
At 12 months in a phase 1/2 trial, the Bimatoprost Drug Pad-IOL System improved IOP, vision and treatment burden in patients ...
Johnson & Johnson (JNJ) wins FDA approval for Tecnis PureSee intraocular lens ((IOL)), giving eye surgeons a new lens option for use in cataract surgery. Read more here.
Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to 0.
Two non-bioerodible pads at the optic–haptic junction of a monofocal IOL release bimatoprost into aqueous humor for >3 years while remaining outside the visual axis. Randomization (2:1:1) compared 78 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results